GUEST COLUMNISTS

CLINICAL TRIAL WHITE PAPERS

  • The Importance Of Decentralized Clinical Trials
    7/27/2021

    While the standards and value of clinical trials remain high, new implementation techniques have allowed for the adoption of decentralized clinical trials. Download the available white paper to find out more.

  • Patient Centricity And Virtualizing Technologies In A COVID-19 World
    1/29/2021

    As the COVID-19 pandemic rages on, clinical trial conduct is being reimagined in ways few thought possible not so long ago. Patient centricity is a growing and important movement within clinical trials. New information is constantly filtering in as to how sites are adapting to the COVID-19 era, and how patient-centric solutions are playing a growing role. The Society for Clinical Research Sites (SCRS) recently collaborated with Medidata (a Dassault Systemes Company) to conduct an online survey to measure current and anticipated levels of adoption of patient-centric tools, and the sites’ perspective on how patients have reacted to them.

  • Guide To Digital Endpoints In Rheumatology Research
    11/14/2022

    In rheumatology, learn why both the FDA and EMA have highlighted the need to assess physical function and walking as key efficacy endpoints.

  • Phlexglobal Innovation Tour 2020: Industry Survey Results & Expert Analysis
    1/25/2021

    On July 15, 2020, we launched the Phlexglobal Innovation Tour to bring together experts from across our industry to discuss clinical and regulatory related topics and explore innovative approaches to making compliance faster, easier, and better. What follows are the results of focused audience polls done during each session and afterwards together with the thoughts of our Innovation Tour experts

  • The Future Of Health Data: A 2022 Life Sciences Industry Insights Report
    11/14/2022

    A survey of life sciences leaders reveals some of the key challenges that come with using real-world data (RWD) for innovation, along with their vision and predictions for how RWD can accelerate drug development and improve patient outcomes.

CLINICAL TRIAL APP NOTES & CASE STUDIES

  • Ora Streamlines Clinical Trials With Veeva Vault CTMS And BA Insight AppBus Platform
    2/16/2021

    Ora, a full-service contract research organization specializing in ophthalmology, aims to accelerate development timelines for its sponsor clients, so productivity and efficiency are critical to delivering high-quality engagements. To achieve its goal of providing best-in-class clinical services, Ora easily integrates Vault CTMS with other applications using the BA Insight AppBus low-code platform.

  • How Workflow Software Can Shift Space And Time
    6/29/2021

    Workflow software has the power to literally shift space and time. In this article we share some examples of how software can expand access for any process and describe specific applications and benefits for clinical research.

  • Study Start-Up And Enrollment
    7/27/2021

    IQVIA Biotech was approached by a clinical-stage biopharmaceutical company to run its Phase II prostate cancer drug trial in the U.S. For more information, download the available case study.

  • Preparing For The Next Pandemic: Lessons Learned
    8/18/2021

    COVID-19 impacted how clinical trials are conducted and emphasized the need to stay ahead of emerging viruses and diseases. Explore insights on which measures and approaches will most likely continue to be implemented in the future.

  • Decentralized Trials For Duchenne Muscular Dystrophy
    9/21/2021

    Working closely with a global biotechnology company on a mission to engineer precision genetic medicine for rare diseases, MRN has delivered more than 180 home visits per month to keep trials running across a vulnerable, pediatric population during the COVID-19 pandemic.

  • Simulation-Based Training For Better Decisions
    10/5/2021

    Learning through simulation has historically been reserved for industries where even the smallest errors have major consequences. Clinical research is late to the party, only now realizing that the consequences of poorly trained staff, ranging from protocol deviations to site failures, can be avoided.

CLINICAL LEADER CONTENT COLLECTIONS

22_04_CL_CROSelection_Ebook_300x200

 

The articles in this e-book all relate to the challenge of CRO selection. We hope you enjoy them and learn from the insights contained in them.

More Content Collections

FOCUS ON PATIENTS

  • Drug developers often talk about “patient centricity,” but most find it challenging to prioritize a patient-centric research approach in the earlier phases of drug development. A good place to start is by collectively measuring what matters most to patients — and COAs help get us there.

  • The EMA now requires Plain Language Summaries (PLS) for clinical trials with sites in the EU. The FDA has no current regulations for PLS, but they fit into recent guidance documents. PLS meet the needs of trial participants, their families, and patient advocacy groups, among others. Optimize your PLS with these tips.

  • Between 2000 and 2020, nearly 80% of clinical trial participants were white. The underrepresentation of diverse racial and ethnic groups is not new, but we must do more to address disparities. Here are five strategies for action.

EMBRACING DIVERSITY & INCLUSION

  • Latin America is a compelling region to conduct medtech early feasibility studies due to its ethnically diverse population, its high rate of urbanization, and more. Here, the author spotlights Colombia, Brazil, and Mexico as the hotspots for medtech feasibility studies in Latin America. 

  • Intersectionality is the framework for how a person’s relationships, identities, interactions, and interdependencies can create different advantages and disadvantages. In order to fully embrace intersectionality and make meaningful impacts in clinical trial recruitment of diverse populations, the entire journey of the patient must be realized — every step of the way.

  • Between 2000 and 2020, nearly 80% of clinical trial participants were white. The underrepresentation of diverse racial and ethnic groups is not new, but we must do more to address disparities. Here are five strategies for action.